medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2011, Number 3

<< Back Next >>

Salud Mental 2011; 34 (3)

Revisión de la literatura médica sobre el manejo de las depresiones resistentes/refractarias al tratamiento

Tamayo JM, Rosales-Barrera JI, Villaseñor-Bayardo SJ, Rojas-Malpica C

Language: Spanish
References: 92
Page: 257-266
PDF size: 138.19 Kb.


ABSTRACT

Major depressive disorder (MDD) is a prevalent and costly disease that is usually associated with high rates of disability. The target for the treatment of MDD is to achieve and maintain remission or complete control of depressive symptoms by the choice of an effective antidepressant.
Sometimes, despite evidence based-treatment, it is possible that the patient does not have a favorable response. Although there is an increasing number of antidepressants available to treat depression, approximately half of the patients do not respond and two-thirds do not achieve remission after first-line treatment. In these cases we refer to treatment-resistant depression (TRD) as is defined in an article in this issue of Salud Mental. The TRD is one of the most complex conditions in psychiatry from the therapeutic point of view due to different definitions, algorithms, and response criteria, especially in Latin America where the procedures based on regional needs and consensus are scarce and not always based on evidence.
It was conducted a systematic review using several databases such as MEDLINE, PsycINFO, EMBASE, the Cochrane Library and LILACS from 1949 to March 2011 crossing terms which allowed the inclusion of relevant articles in the management of the TRD. Unfortunately, the original publications in Latin America are often based on TRD case report, so the results and conclusions of this review have been based entirely on Anglo-Saxon scientific production.
The therapeutic strategies used in the TRD are many, and include combinations of antidepressants or other psychotropic agents, in some cases addition of psychotherapy and, in extreme cases, neurostimulation techniques such as electroconvulsive therapy (ECT). The study Sequenced Treatment Alternatives to Relieve Depression (STARD) is the largest trial of treatment for MDD conducted in real practice settings, and the first to study remission as a measure of pre-defined primary outcome. It consists of four different stages of resistance. It is clear that there are diminishing remission rates as the number of treatment trials increases.
The strategies include: antidepressant dose optimization, addition of medications like thyroid hormone, lithium, or nutritional supplements, a combination of antidepressants, and addition of second-generation antipsychotics (SGAs). Evidence suggests that remission rates can be from 25% to 50%, although with some differences among the drugs recommended. Evidence supports the use of SGAs for increasing the level of remission of new-generation antidepressants, although neither the profit nor the long-term benefits of this strategy have been well established.
Neuro-modulation techniques include ECT, repetitive transcranial magnetic stimulation (rTMS), deep brain stimulation (DBS), and vagus nerve stimulation (VNS). ECT remains a first line option for the treatment of DRT with response rates ranging from 50% to 89%.
Finally, the effectiveness of cognitive-behavioral therapy (CBT) in the management of the DRT could be a useful alternative when practiced in conjunction with any of the pharmacological strategies. However, further studies are needed to recommend it as first line treatment.


REFERENCES

  1. Panzarino P Jr. The costs of depression: direct and indirect; treatment versus non-treatment. J Clin Psychiatry 1998;59(supl 20):11-14.

  2. Souery D, Mendlewicz J. Compliance and therapeutic issues in resistant depression. Int Clin Psychopharmacol 1998;13(supl 2):S13-S18.

  3. Trivedi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40.

  4. Tamayo JM, Rosales-Barrera J, Villaseñor-Bayardo S, Rojas-Malpica C. Definición e impacto de las depresiones resistentes/refractarias al tratamiento. Salud Mental 2011;34.

  5. Malhi GS, Parker GB, Crawford J et al. Treatment-resistant depression: resistant to definition? Acta Psychiatr Scand 2005;112:302-309.

  6. Keller MB. Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 2003;289:3152-3160.

  7. Warden D, Rush AJ, Trivedi MH et al. The STAR*D project results: a comprehensive review of findings. Curr Psychiatry Rep 2007;9:449-459.

  8. Joffe RT, Levitt AJ, Sokolov ST et al. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry 1996;57:114-115.

  9. Baldomero EB, Ubago JG, Cercos CL et al. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress Anxiety 2005;22:68-76.

  10. Thase ME, Feighner JP, Lydiard RB. Citalopram treatment of fluoxetine non-responders. J Clin Psychiatry 2001;62:683-687.

  11. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-Resistant Depression: A Meta-Analysis Comparing Within- Versus Across-Class Switches. Biol Psychiatry 2008;63:699-704.

  12. Poirier M-F, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression: double-blind, randomised comparison. Br J Psychiatry 1999;175:12-16.

  13. Rush AJ, Trivedi MH, Wisniewski SR et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354:1231-1242.

  14. Lenox-Smith AJ, Jiang Q. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Int Clin Psychopharmacol 2008;23:113-119.

  15. Wohlreich MM, Martinez JM, Mallinckrodt CH et al. An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches. J Clin Psychopharmacol 2005;25:552-560.

  16. Fava M, Dunner DL, Greist JH et al. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry 2001;62:413-420.

  17. Nierenberg AA, Papakostas GI, Petersen T et al. Nortriptyline for treatment- resistant depression. J Clin Psychiatry 2003;64:35-39.

  18. Nolen WA, van de Putte JJ, Dijken WA et al. Treatment strategy in depression, 2: MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatr Scand 1988;78:676–683.

  19. Nolen WA, Haffmans PM, Bouvy PF et al. Monoamine oxidase inhibitors in resistant major depression: a double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants. J Affect Disord 1993;28:189–197.

  20. Thase ME, Mallinger AG, McKnight D et al. Treatment of imipramineresistant recurrent depression, IV: a double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992;149:195-198.

  21. Rush AJ, Trivedi MH, Wisniewski SR et al. Bupropion SR, sertraline, or venlafaxine XR after failure of SSRIs for depression. N Engl J Med 2006;354:1231-1242.

  22. Fava M, Rush AJ, Wisniewski SR et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006;163:1161-1172.

  23. McGrath PJ, Stewart JW, Fava M et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006;163:1531-1541.

  24. aan het Rot M, Collins KA, Murrough JW et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010;67:139-145.

  25. Mathew SJ, Murrough JW, aan het Rot M, et al. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 2010;13:71-82.

  26. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two metaanalyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007;68:935-940.

  27. Rush AJ, Trivedi JH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-1917.

  28. Altshuler LL, Bauer M, Frye MA et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 2001;158:1617-1622.

  29. Aronson R, Offman HJ, Joffe RT et al. Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. Arch Gen Psychiatry 1996;53:842-848.

  30. Nierenberg AA, Fava M, Trivedi MH et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006;163:1519-1530.

  31. Patkar AA, Masand PS, Pae CU et al. A randomized, double-blind, placebocontrolled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol 2006;26:653-656.

  32. Ravindran AV, Kennedy SH, O’Donovan MC et al. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo controlled trial. J Clin Psychiatry 2008;69:87-94.

  33. Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005;66:85-93.

  34. Michelson D, Adler LA, Amsterdam JD et al. Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, doubleblind, placebocontrolled study. J Clin Psychiatry 2007;68:582-587.

  35. Bordet R, Thomas P, Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo controlled trial. Am J Psychiatry 1998;155: 1346-1351.

  36. Perez V, Soler J, Puigdemont D et al. A double-blind, randomized, placebocontrolled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Arch Gen Psychiatry 1999; 56:375-379.

  37. Ballesteros J, Callado LF. Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. J Affect Disord 2004;79:137-147.

  38. Landen M, Bjorling G, Agren H et al. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment refractory depression. J Clin Psychiatry 1998;59:664-668.

  39. Appelberg BG, Syvalahti EK, Koskinen TE et al. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 2001;62:448-452.

  40. Papakostas GI, Petersen T, Mischoulon D et al. Serum folate, vitamin B12, and homocysteine in major depressive disorder, pt 1: predictors of clinical response in fluoxetine-resistant depression. J Clin Psychiatry 2004;65:1090-1095.

  41. Papakostas GI, Petersen T, Mischoulon D et al. Serum folate, vitamin B12, and homocysteine in major depressive disorder, pt 2: predictors of relapse during the continuation phase of pharmacotherapy. J Clin Psychiatry 2004;65:1096-1098.

  42. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomized, placebo controlled trial. J Affect Disord 2000;60:121-130.

  43. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002;159:477-479.

  44. Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 2007;68:1056-1061.

  45. Papakostas GI, Mischoulon D, Shyu I et al. S-Adenosyl Methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: A double-blind, randomized clinical trial. Am J Psychiatry 2010;167:942–948.

  46. Nelson J, Mazure C, Jatlow P et al. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 2004;55:296-300.

  47. Fava M, Alpert J, Nierenberg A et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol 2002;22:379-387.

  48. Rush AJ, Warden D, Wisniewski SR. STAR*D. Revising Conventional Wisdom. CNS Drugs 2009;23:627-647.

  49. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 2002;51:183-188.

  50. Blier P, Ward HE, Tremblay P et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010;167:281-288.

  51. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: A meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009;166:980-991.

  52. Shelton RC, Tollefson GD, Tohen M et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-134.

  53. Shelton RC, Williamson DJ, Corya SA. Olanzapine/fluoxetine combination for treatment-resistant depression: A controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005;66:1289-1297.

  54. Corya SA, Williamson D, Sanger TM. A Randomized, Double-blind comparison Of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006;23:364-372.

  55. Thase ME, Corya SA, Osuntokun O et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007;68:224-236.

  56. Rapaport MH, Gharabawi GM, Canuso CM et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 2006;31:2505-2513.

  57. Mahmoud RA, Pandina GJ, Turkoz I et al. Risperidone for treatmentrefractory major depressive disorder: a randomized trial. Ann Intern Med 2007;147:593-602.

  58. Keitner GI, Garlow SJ, Ryan CE et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 2009;43:205-214.

  59. Berman RM, Marcus RN, Swanink R et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68:843-853.

  60. Marcus RN, McQuade RD, Carson WH et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008;28:156-165.

  61. Berman RM, Fava M, Thase ME et al. Aripiprazole augmentation in major depressive disorder: A double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009;14:197-206.

  62. Bauer M, El-Khalili N, Datto C et al. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord 2010;127:19-30.

  63. Corya SA, Andersen SW, Detke HC et al. Long-Term Antidepressant Efficacy and Safety of Olanzapine/Fluoxetine Combination: A 76-Week Open-Label Study. J Clin Psychiatry 2003;64:1349-1356.

  64. Thase ME, Rush AJ. Treatment-resistant depression, in Bloom FE, Kupfer DJ (eds): Psychopharmacology: The fourth generation of progress. New York: Raven Press; 1995; pp 1081-1097.

  65. Folkerts HW, Michael N, Tolle R et al. Electroconvulsive therapy vs. paroxetine in treatment-resistant depression: a randomized study. Acta Psychiatr Scand 1997;96:334-342.

  66. Devanand DP, Sackeim HA, Prudic J. Electroconvulsive therapy in the treatment-resistant patient. Psychiatr Clin North Am 1991;14:905-923.

  67. Sackheim HA. Continuation therapy following ECT: Directions for future research. Psychopharmacol Bull 1994;30:501-521.

  68. Petrides G, Dhossche D, Fink M et al. Continuation ECT: Relapse prevention in affective disorders. Convuls Ther 1994;10:189-194.

  69. Rush AJ, Sackeim HA, Marangell LB et al. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry 2005;58:355-363.

  70. George MS, Rush AJ, Marangell LB et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry 2005;58:364-373.

  71. Rush AJ, Marangel, LB, Sackeim HA et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005;58:347-354.

  72. Daban C, Martinez-Aran A, Cruz N et al. Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review. J Affect Disord 2008;110:1-15.

  73. Chouinard PA, Van Der Werf YD, Leonard G et al. Modulating neural networks with transcranial magnetic stimulation applied over the dorsal premotor and primary motor cortices. J Neurophysiol 2003;90:1071-1083.

  74. Holtzheimer PE, Avery D, Schlaepfer TE. Antidepressant effects of repetitive transcranial magnetic stimulation. Br J Psychiatry 2004;184:541-542.

  75. Martin JL, Barbanoj MJ, Schlaepfer TE et al. Repetitive transcranial magnetic stimulation for the treatment of depression: Systematic review and meta-analysis. Br J Psychiatry 2003;182:480-491.

  76. Schlaepfer TE, Kosel M, Nemeroff CB. Efficacy of repetitive transcranial magnetic stimulation (rTMS) in the treatment of affective disorders. Neuropsychopharmacol 2003;28:201-205.

  77. Gershon AA, Dannon PN, Grunhaus L. Transcranial magnetic stimulation in the treatment of depression. Am J Psychiatry 2003;160:835-845.

  78. Avery DH, Holtzheimer III PE, Fawaz W et al. A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression. Biol Psychiatry 2006;59:187-194.

  79. Fitzgerald PB, Benitez J, De Castella A et al. A randomized, controlled trial of sequential bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression. Am J Psychiatry 2006;163:88-94.

  80. Brunoni AR, Teng CT, Correa C et al. Neuromodulation approaches for the treatment of major depression. Challenges and recommendations from a working group meeting. Arq Neuropsiquiatr 2010;68:433-451.

  81. Dougherty DD, Weiss AP, Cosgrove GR et al. Cerebral metabolic correlates as potential predictors of response to anterior cingulotomy for treatment of major depression. J Neurosurg 2003;99:1010-1017.

  82. Greenberg BD, Price LH, Rauch SL et al. Neurosurgery for intractable obsessive-compulsive disorder and depression: Critical issues. Neurosurg Clin N Am 2003;14:199-212.

  83. Sachdev PS, Sachdev J. Long-term outcome of neurosurgery for the treatment of resistant depression. J Neuropsychiatry Clin Neurosci 2005;17:478-485.

  84. Lozano AM, Mayberg HS, Giacobbe P et al. Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry 2008;64:461-467.

  85. Bewernick BH, Hurlemann R, Matusch A et al. Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biol Psychiatry 2010;67:110-116.

  86. Hollon SD, DeRubeis RJ, Shelton RC et al. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry 2005;62:417-422.

  87. Fava GA, Savron G, Grandi S et al. Cognitive-behavioral management of drug-resistant major depressive disorder. J Clin Psychiatry 1997;58:278-282.

  88. McPherson S, Cairns P, Carlyle J et al. The effectiveness of psychological treatments for treatment-resistant depression: a systematic review. Acta Psychiatr Scand 2005;111:331-340.

  89. Bannan N. Multimodal therapy of treatment resistant depression: a study and analysis. Int J Psychiatry Med 2005;35:27-39.

  90. Teasdale JD, Scott J, Moore RG et al. How does cognitive therapy prevent relapse in residual depression? Evidence from a controlled trial. J Consult Clin Psychol 2001;69:347-357.

  91. Keller MB, McCullough JP,Klein DN et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342:1462-1470.

  92. Brent D, Emslie G, Clarke G et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008;299:901-913.




2020     |     www.medigraphic.com